

ACE2 Antibody (N-term K187) Blocking Peptide

Synthetic peptide Catalog # BP6020g

Specification

ACE2 Antibody (N-term K187) Blocking Peptide - Product Information

Primary Accession

Q9BYF1

ACE2 Antibody (N-term K187) Blocking Peptide - Additional Information

Gene ID 59272

Other Names

Angiotensin-converting enzyme 2, ACE-related carboxypeptidase, Angiotensin-converting enzyme homolog, ACEH, Metalloprotease MPROT15, Processed angiotensin-converting enzyme 2, ACE2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP6020g was selected from the N-term region of human ACE2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ACE2 Antibody (N-term K187) Blocking Peptide - Protein Information

Name ACE2 (HGNC:13557)

Function

Essential counter-regulatory carboxypeptidase of the renin- angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis (PubMed:<a href="http://www.uniprot.org/citations/27217402" http://www.uniprot.org/citations/27217402" http://www.uniprot.org/citations/27217402" http://www.uniprot.org/citations/27217402" http://www.uniprot.org/citations/27217402" http://www.uniprot.org/citations/27217402" http://www.uniprot.org/citations/27217402" https://www.uniprot.org/citations/27217402" https://www.uniprot.org/citations

target="_blank">27217402). Converts angiotensin I to angiotensin 1- 9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II (PubMed:<a

 $href="http://www.uniprot.org/citations/10924499" target="_blank">10924499, PubMed:10969042, PubMed:11815627, PubMed:14504186, PubMed:14504186</a href="http://www.uniprot.org/citations/14504186" target="_blank">14504186</a href="http://www.uniprot.org/citations/14504186" target="_blank">14504186</a href="http://www.uniprot.org/cita$



href="http://www.uniprot.org/citations/19021774" target="_blank">19021774). Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin (PubMed:10969042, PubMed:11815627). Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin- 7, neocasomorphin) and dynorphin A with high efficiency (PubMed:11815627, PubMed:27217402, PubMed:28293165). In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity (PubMed:18424768, PubMed:19185582).

Cellular Location

[Processed angiotensin-converting enzyme 2]: Secreted [Isoform 2]: Apical cell membrane

Tissue Location

Expressed in endothelial cells from small and large arteries, and in arterial smooth muscle cells (at protein level) (PubMed:15141377). Expressed in enterocytes of the small intestine, Leydig cells and Sertoli cells (at protein level) (PubMed:15141377) Expressed in the renal proximal tubule and the small intestine (at protein level) (PubMed:18424768). Expressed in heart, kidney, testis, and gastrointestinal system (at protein level) (PubMed:10924499, PubMed:10969042, PubMed:12459472, PubMed:15231706, PubMed:15671045, PubMed:32170560, PubMed:32715618). In lung, expressed at low levels in some alveolar type 2 cells, the expression seems to be individual- specific (at protein level) (PubMed:15141377, PubMed:32170560, PubMed:32425701, PubMed:32715618, PubMed:33432184). Expressed in nasal epithelial cells (at protein level) (PubMed:323333915, PubMed:33432184) Coexpressed with TMPRSS2 within some lung alveolar type 2 cells, ileal absorptive enterocytes, intestinal epithelial cells, cornea, gallbladder and nasal goblet secretory cells (PubMed:32327758, PubMed:32358202, PubMed:32413319). Coexpressed with TMPRSS4 within mature enterocytes (PubMed:32404436).

ACE2 Antibody (N-term K187) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

ACE2 Antibody (N-term K187) Blocking Peptide - Images

ACE2 Antibody (N-term K187) Blocking Peptide - Background

ACE2 cDNA encodes a deduced 805-amino acid protein containing a potential 17-amino acid N-terminal signal peptide and a putative 22-amino acid C-terminal membrane anchor. It also possesses a zinc metalloprotease consensus sequence and a conserved glutamine residue that may function as a third zinc ligand. ACE2 is expressed predominantly in vascular endothelial cells of the heart and kidney. ACE converts angiotensin I to angiotensin II, ACE2 converts angiotensin I to angiotensin 1-9, which has 9 amino acids. Angiotensin II is a potent blood vessel constrictor, while angiotensin 1-9 does not impact blood vessels but is cleaved by ACE to a shorter peptide, angiotensin 1-7, which is a blood vessel dilator. Spike (S) proteins of coronaviruses, including the SARS coronavirus, bind with cellular receptors to mediate infection of target cells. ACE2 binds the S1 domain of the SARS coronavirus S protein. SARS coronavirus replicates efficiently on ACE2-transfected but not mock-transfected 293T cells. Anti-ACE2 but not anti-ACE1 antibody blocks viral replication on Vero E6 cells. It has been proposed that ACE2 is a functional receptor for SARS



coronavirus.

ACE2 Antibody (N-term K187) Blocking Peptide - References

Douglas, G.C., et al., Endocrinology 145(10):4703-4711 (2004).Turner, A.J., et al., Trends Pharmacol. Sci. 25(6):291-294 (2004).Towler, P., et al., J. Biol. Chem. 279(17):17996-18007 (2004).Wong, S.K., et al., J. Biol. Chem. 279(5):3197-3201 (2004).Li, W., et al., Nature 426(6965):450-454 (2003).